Investigation of the anti-inflammatory mechanism of beta2 adrenergic receptor-IL-6 axis activation

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K07118
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47040:Pharmacology-related
• Research Institution: Tokyo University of Agriculture and Technology
• Principal Investigator: Eriko Suzuki 東京農工大学, (連合)農学研究科(研究院), 准教授 (00468513)
• Co-Investigator(Kenkyū-buntansha): 蓮見 惠司 東京農工大学, (連合)農学研究科(研究院), 教授 (20208474)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 抗炎症作用 / アドレナリン受容体 / IL-6 / 脂肪組織

Outline of Final Research Achievements

We have previously found that SMTP, a bioactive compound which shows excellenct anti-inflammatory effect in various animal models via the inhibition of soluble epoxide hydrolase (sEH). In this study, we have demonstrated that the anti-inflammatory effect was due to a gradual increase of plasma IL-6, a pleiotropic cytokine responsible for the regulation of inflammation. We also found that beta2 adrenergic receptor activation mainly in muscle and adipose tissue is involved as a responsible mechanism, and that enhancement of b2AR-IL-6 signal by N-phos inhibition is essential for the regulation of inflammation.

Free Research Field

細胞生物学

Academic Significance and Societal Importance of the Research Achievements

炎症が関与する疾患は多種多様であり、それゆえ炎症の制御は疾病の治療・予防や人々のQOLの向上に寄与する重要な命題である。本研究において報告した、アドレナリン受容体を介したIL-6発現の緩徐な上昇を介した炎症制御メカニズム、また可溶性エポキシドヒドロラーゼN末端ホスファターゼ阻害によるこのシグナルの増強は、炎症制御の新しい作用点を提唱するものであり、新規治療薬開発や炎症性疾患の発症・増悪化の機序の解明に貢献しうる、新しい発見である。